Roche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Roche Holding AG (OTCMKTS:RHHBY) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company.

Roche Trading Down 0.3%

Shares of OTCMKTS:RHHBY opened at $40.77 on Tuesday. Roche has a 1-year low of $34.10 and a 1-year high of $44.31. The business’s 50 day moving average is $40.10 and its 200-day moving average is $40.30. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.48 and a quick ratio of 1.20.

Hedge Funds Weigh In On Roche

Several institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its stake in shares of Roche by 6,463.8% in the 1st quarter. GAMMA Investing LLC now owns 528,778 shares of the company’s stock valued at $21,759,000 after buying an additional 520,722 shares during the period. Boston Common Asset Management LLC increased its stake in shares of Roche by 11.1% in the 2nd quarter. Boston Common Asset Management LLC now owns 361,833 shares of the company’s stock valued at $14,682,000 after buying an additional 36,101 shares during the period. Bard Financial Services Inc. increased its stake in shares of Roche by 25.3% in the 1st quarter. Bard Financial Services Inc. now owns 138,900 shares of the company’s stock valued at $5,716,000 after buying an additional 28,050 shares during the period. Minot DeBlois Advisors LLC acquired a new stake in shares of Roche in the 4th quarter valued at $752,000. Finally, Corient IA LLC acquired a new stake in shares of Roche in the 1st quarter valued at $616,000.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.